First Trust Advisors LP Takes $943,000 Position in AtriCure Inc. (NASDAQ:ATRC)

Share on StockTwits

First Trust Advisors LP purchased a new stake in shares of AtriCure Inc. (NASDAQ:ATRC) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 37,803 shares of the medical device company’s stock, valued at approximately $943,000. First Trust Advisors LP owned 0.10% of AtriCure as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently made changes to their positions in ATRC. Invesco Ltd. raised its stake in shares of AtriCure by 4,185.4% during the second quarter. Invesco Ltd. now owns 382,256 shares of the medical device company’s stock valued at $11,406,000 after purchasing an additional 373,336 shares in the last quarter. Waddell & Reed Financial Inc. bought a new stake in shares of AtriCure during the second quarter valued at about $10,825,000. GW&K Investment Management LLC raised its stake in shares of AtriCure by 73.2% during the second quarter. GW&K Investment Management LLC now owns 843,747 shares of the medical device company’s stock valued at $25,177,000 after purchasing an additional 356,652 shares in the last quarter. Nuveen Asset Management LLC raised its stake in shares of AtriCure by 418.5% during the second quarter. Nuveen Asset Management LLC now owns 423,336 shares of the medical device company’s stock valued at $12,632,000 after purchasing an additional 341,689 shares in the last quarter. Finally, Tamarack Advisers LP raised its stake in shares of AtriCure by 58.8% during the second quarter. Tamarack Advisers LP now owns 675,000 shares of the medical device company’s stock valued at $21,195,000 after purchasing an additional 250,000 shares in the last quarter. 89.22% of the stock is owned by institutional investors.

Shares of AtriCure stock opened at $29.75 on Monday. The company has a current ratio of 3.11, a quick ratio of 2.49 and a debt-to-equity ratio of 0.29. The company’s 50-day moving average price is $27.75 and its two-hundred day moving average price is $28.46. AtriCure Inc. has a 52 week low of $22.57 and a 52 week high of $34.39. The stock has a market cap of $1.18 billion, a PE ratio of -31.65 and a beta of 0.27.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Wednesday, October 30th. The medical device company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.03. AtriCure had a negative net margin of 10.13% and a negative return on equity of 13.59%. The firm had revenue of $56.60 million for the quarter, compared to analysts’ expectations of $55.12 million. During the same period in the previous year, the business earned ($0.24) earnings per share. AtriCure’s revenue for the quarter was up 13.4% compared to the same quarter last year. On average, equities analysts predict that AtriCure Inc. will post -1.11 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on the stock. ValuEngine upgraded shares of AtriCure from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Zacks Investment Research upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a research note on Monday, November 4th. Piper Jaffray Companies set a $40.00 price objective on shares of AtriCure and gave the company a “buy” rating in a research note on Monday, August 12th. BTIG Research restated a “buy” rating and set a $35.00 price objective on shares of AtriCure in a research note on Tuesday, August 13th. Finally, Needham & Company LLC set a $39.00 price objective on shares of AtriCure and gave the company a “buy” rating in a research note on Monday, August 12th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $36.00.

In other AtriCure news, COO Douglas J. Seith sold 48,804 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $25.63, for a total transaction of $1,250,846.52. Following the sale, the chief operating officer now owns 208,281 shares in the company, valued at approximately $5,338,242.03. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO M. Andrew Wade sold 11,705 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $30.00, for a total value of $351,150.00. Following the sale, the chief financial officer now owns 144,715 shares in the company, valued at approximately $4,341,450. The disclosure for this sale can be found here. 8.00% of the stock is currently owned by insiders.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.

Read More: Why are percentage decliners important?

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.